Copyright
©The Author(s) 2015.
World J Hepatol. Jun 28, 2015; 7(12): 1685-1693
Published online Jun 28, 2015. doi: 10.4254/wjh.v7.i12.1685
Published online Jun 28, 2015. doi: 10.4254/wjh.v7.i12.1685
Table 3 Comparison of baseline characteristics (effective vs ineffective with tolvaptan)
| Characteristic | Effective (n = 38) | Ineffective (n = 22) | P |
| Dosing period (d) | 73 (12-109) | 22 (7-36) | 0.02 |
| TLV (mg/d) | 7.5 (7.5-7.5) | 7.5 (7.5-7.5) | 0.36 |
| Age (yr) | 66.7 ± 11.1 | 67.0 ± 11.4 | 0.95 |
| Male | 33 (86.8%) | 13 (59.1%) | 0.02 |
| Bodyweight (kg) | 62 (54-68) | 60 (48-71) | 0.58 |
| 1Bodyweight (kg) | 3.6 (2.1-4.7) | 0.2 (0.1-0.8) | < 0.01 |
| HCV antibody positive | 27 (71.1%) | 9 (40.9%) | 0.03 |
| Child-Pugh class C | 11 (28.9%) | 16 (72.7%) | < 0.01 |
| Refractory ascites | 35 (92.1%) | 32 (95.5%) | 1.00 |
| Hepatic hydrothorax | 21 (55.3%) | 11 (50.0%) | 0.79 |
| Liver neoplasms stage 3, 4a, or 4b | 11 (28.9%) | 15 (68.2%) | < 0.01 |
| Serum albumin (g/dL) | 2.9 (2.6-3.2) | 2.7 (2.3-3.0) | 0.20 |
| Total bilirubin (mg/dL) | 1.7 (0.7-1.9) | 4.5 (1.5-6.3) | < 0.01 |
| ALT (IU/L) | 37 (20-41) | 50 (25-77) | 0.18 |
| Serum creatinine (mg/dL) | 1.53 (0.89-2.09) | 1.17 (0.95-1.40) | 0.11 |
| eGFR (mL/min per 1.73 m2) | 49.8 (26.7-62.7) | 51.7 (34.6-62.5) | 0.80 |
| Serum sodium (mEq/L) | 134 (132-138) | 131 (128-136) | 0.03 |
| Platelet count (× 103/μL) | 107 (58-144) | 127 (65-190) | 0.27 |
| Prothrombin activity (%) | 61.5 (46.3-73.2) | 53.8 (41.2-64.2) | 0.10 |
- Citation: Ohki T, Sato K, Yamada T, Yamagami M, Ito D, Kawanishi K, Kojima K, Seki M, Toda N, Tagawa K. Efficacy of tolvaptan in patients with refractory ascites in a clinical setting. World J Hepatol 2015; 7(12): 1685-1693
- URL: https://www.wjgnet.com/1948-5182/full/v7/i12/1685.htm
- DOI: https://dx.doi.org/10.4254/wjh.v7.i12.1685